By Katherine Hamilton
Regeneron Pharmaceuticals won $406.8 million in damages for a lawsuit claiming Amgen violated antitrust and tort laws.
A jury in a Delaware court found that Amgen violated certain laws, and gave Regeneron $135.6 million in compensatory damages and $271.2 million in punitive damages.
Regeneron had alleged in a lawsuit that Amgen was purposely excluding Regeneron's anti-inflammatory cholesterol drug Praluent from the marketplace.
The pharmaceutical company claimed Amgen bundled anti-inflammatory drugs Enbrel and Otezla to convince pharmacy benefit managers to select Repatha as the exclusive PCSK9 category product over Praluent. Amgen also threatened to withhold rebates to the managers unless they chose Repatha over Praluent, the company alleged.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
May 15, 2025 15:18 ET (19:18 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.